Rayner appoints esteemed ophthalmic leaders as strategic advisors and is awarded IDE for trifocal IOLs
Posted on 22/12/2021
DECEMBER 22, 2021 – Worthing, United Kingdom. Rayner, a leading UK-based ophthalmic company focused on optimising visual outcomes for surgeons and their patients, is delighted to announce the appointment of Drs Eric Donnenfeld, Kerry Solomon, Vance Thompson, and Mr Jim Mazzo as strategic advisors to the business, with a specific focus on supporting the expansion
Rayner acquires Omidria to expand surgical offering in USA and Europe
Posted on 7/12/2021
DECEMBER 02, 2021 – Worthing, United Kingdom. Rayner Surgical Group (‘Rayner’) and Omeros Corporation (‘Omeros’) are delighted to announce the transfer of Omeros’ ophthalmology assets, including OmidriaTM, to Rayner. This will enable the creation of a significant commercial, regulatory and marketing infrastructure in the US, with a broad range of products, including intraocular lenses (IOLs), for cataract surgeons.
Rayner Receives Third FDA Approval in RayOne IOL Portfolio
Posted on 17/05/2021
New York, USA, May 17, 2021 – RayOne Spheric, a fully-preloaded monofocal IOL, has received FDA approval. This achievement marks Rayner’s third FDA approval in under three years within its expanding RayOne preloaded IOL portfolio. RayOne Spheric joins RayOne Aspheric (FDA approved December 2018) and RayOne EMV, a new non-diffractive IOL solution which achieved FDA